OBJECTIVE:To investigate the efficacy and safety of modified Wendan decoction combined with levamlodipine besylate in the treatment of hypertension .METHODS:90 patients with essential hypertensive treated in the hospital from Oct.2012 to Oct.2014 were selected as the research objects.According to the random number table method, the patients were divided into the observation group and the control group , with 45 cases in each group .The control group were treated with levamlodipine besylate , while the observation group were additionally treated with modified Wendan decoction, on the basis of the control group .The vascular endothelial function and the improvement of blood pressure and clinical efficacy in the two group were observed .RESULTS:8 weeks of treatment later , the total effective rate in the observation group [93.33%(42/45)] was significantly higher than that in the control group [77.78%(35/45)].The diastolic and systolic blood pressure of the observation group were significant lower than those of the control group ( P<0.05).The control rate of blood pressure of the observation group [93.33%(42/45)] was significantly higher than that of the control group [75.56%(34/45) ];The falling range of diastolic blood pressure of the observation group was significantly higher than that of the control group, but the treatment cost was significantly lower than that of the control group (P<0.05). In the observation group , NO (7.13 ±1.42)μmol/L was significantly lower than that in the control group , while heart rate (68.72 ±8.37) time/min and blood urea nitrogen (4.36 ±0.51) mmol/L were significantly lower than those in the control group [(76.28 ±10.19)time/min and(4.97 ±0.69) mmol/L] (P<0.05).CONCLUSIONS:Modified Wendan decoction combined with levamlodipine besylate in the treatment of hypertension can control the blood pressure to the normal level , reduce the damage of vascular endothelium and improve cardiac and renal function without any obvious adverse reactions .It is worthy of clinical promotion .%目的：探讨温胆汤加味联合苯磺酸左旋氨氯地平治疗高血压病的效果及安全性。方法：选取2012年10月—2014年10月收治的原发性高血压病患者90例作为研究对象，采用随机数字表法分为对照组和观察组各45例，对照组患者予苯磺酸左旋氨氯地平治疗，观察组患者在对照组治疗的基础上予温胆汤加味治疗，观察2组患者血管内皮功能、血压改善情况及临床疗效。结果：治疗8周后，观察组患者治疗总有效率为93.33％（42／45），显著高于对照组的77.78％（35／45）；舒张压和收缩压均显著低于对照组，差异均有统计学意义（P＜0.05）。观察组患者血压达标率为93.33％（42／45），显著高于对照组的75.56％（34／45），舒张压下降幅度显著高于对照组，治疗成本明显低于对照组，差异均有统计学意义（ P＜0.05）。观察组患者NO为（7.13±1.42）μmol／L，显著高于对照组的（4.52±1.49）μmol／L，心率、血尿素氮为（68.72±8.37）次／min、（4.36±0.51） mmol／L，显著低于对照组的（76.28±10.19）次／min、（4.97±0.69） mmol／L，差异均有统计学意义（P＜0.05）。结论：温胆汤加味联合苯磺酸左旋氨氯地平治疗高血压病，可将血压控制在正常水平，减少对内皮血管的损伤，改善患者心、肾功能，且无明显不良反应，值得临床推广。
展开▼
